New York Budget Proposal Threatens Biomarker Testing Coverage for Medicaid Recipients
A recent budget proposal in New York has raised concerns among healthcare advocates about the potential rollback of biomarker testing coverage for Medicaid recipients. Biomarker testing, which has been pivotal in advancing cancer care by allowing for more personalized treatment plans, was expanded in New York three years ago. This expansion was seen as a significant step forward in cancer treatment accessibility. However, the new budget proposal suggests a reduction in coverage, which advocates argue could negatively impact those relying on Medicaid for their healthcare needs. The proposal has sparked a debate about the balance between budget constraints and the necessity of maintaining comprehensive healthcare services. 
